D.E. Shaw & Co
CADL icon

D.E. Shaw & Co’s Candel Therapeutics CADL Stock Holding History

D.E. Shaw & Co’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.12M Buy
+108,933
New +$823K ﹤0.01% 3675
2022
Q2 		– Sell
-10,867
Closed -$55K – 5360
2022
Q1 		$55K Buy
10,867
+745
+7% +$3.7K ﹤0.01% 5123
2021
Q4 		$79K Buy
+10,122
New +$98.3K ﹤0.01% 5117

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $2.67B AUM 169.09% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

D.E. Shaw & Co's CADL Position: Q2 2026 in Review

D.E. Shaw & Co opened a new position in Candel Therapeutics (CADL) in Q2 2026: 108,933 shares worth $1.12M. The stake represents ﹤0.01% of the portfolio and ranks #3675 among its holdings. This is a return to the name: D.E. Shaw & Co previously reported a position in CADL as recently as Q1 2022.

D.E. Shaw & Co first reported a position in CADL in Q4 2021 and has held it in 3 quarters since. 138 funds tracked by Wall St. Rank hold CADL as of Q2 2026.

  • D.E. Shaw & Co held 108,933 shares of Candel Therapeutics worth $1.12M as of Q2 2026.
  • Candel Therapeutics was a new D.E. Shaw & Co position in Q2 2026.
  • Candel Therapeutics made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q2 2026, its #3675 holding.
  • D.E. Shaw & Co first reported a position in Candel Therapeutics in Q4 2021 and has held it in 3 quarters since.
  • 138 funds tracked by Wall St. Rank held Candel Therapeutics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.